Treamid Therapeutics GmbH is focused on developing small molecules aimed at treating respiratory and inflammatory diseases, with a commitment to addressing high unmet medical needs in these areas. The company, founded in 2016, has established a robust pipeline of drug candidates that are under global patent protection. Their research and development efforts are supported by collaborations with esteemed institutions and contract research organizations (CROs), which enhance their capabilities in exploring innovative treatment options. Treamid also operates its own in vitro laboratory, which plays a crucial role in investigating their molecules across various disease contexts.

The company's pipeline includes several promising candidates, such as T01, targeting Long-COVID and COPD-related fibrosis, and T02, which addresses pain and cough. Both candidates are currently in the pre-clinical and Phase I stages of development, indicating ongoing research to validate their efficacy and safety. Treamid's strategic focus on creating easily accessible medications reflects their dedication to improving patient outcomes in respiratory and inflammatory conditions, leveraging their proprietary technologies and scientific expertise to drive advancements in therapeutic options.

Germany

Treamid Therapeutics GmbH was founded in 2016 with the aim to develop new and innovative treatments for respiratory and inflammatory diseases. All our small molecules are under global patent protection.

Our aim is to develop new drugs in the area of high unmet need for respiratory and inflammatory disease, supporting patients with new innovative and easily accessible medications.

We are collaborating with well-renowned institutions and CROs in different fields of our research and development. We also have our own in vitro lab driving our research and developing new methods to further investigate our molecules in different disease areas.

Treamid Therapeutics

Company Details